Thioredoxin 1 delivery as new therapeutics

Adv Drug Deliv Rev. 2009 Apr 28;61(4):303-9. doi: 10.1016/j.addr.2009.01.003.

Abstract

Thioredoxin 1 (Trx 1) is a redox-active small protein ubiquitously present in human body. It is one of the defensive proteins induced in response to various stress conditions. In addition to its anti-oxidative effect by dithiol-disulfide exchange in its active site, Trx 1 has anti-apoptotic and anti-inflammatory effects. Trx 1 overexpression has been shown to be effective in a wide variety of animal models for oxidative and inflammatory disorders. An administration of recombinant Trx 1 protein is also effective in animal models especially for severe acute lung diseases where Trx 1 is likely to act with its anti-inflammatory properties. Trx 1 in circulation shows anti-chemotactic effects for neutrophils and inhibitory effects against macrophage migration inhibitory factor (MIF). Neovascularization is also suppressed by Trx 1 via inhibition of the complement activation. Here we discuss precise mechanisms of Trx 1 and potential therapeutic approach of this molecule.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Chemotactic Factors / antagonists & inhibitors
  • Complement Inactivator Proteins / administration & dosage
  • Complement Inactivator Proteins / physiology
  • Complement Inactivator Proteins / therapeutic use
  • Cytoprotection / physiology
  • Disease Models, Animal
  • Drug Delivery Systems / methods*
  • Humans
  • Neutrophils / pathology
  • Neutrophils / physiology
  • Thioredoxins / administration & dosage*
  • Thioredoxins / physiology
  • Thioredoxins / therapeutic use*

Substances

  • Chemotactic Factors
  • Complement Inactivator Proteins
  • Thioredoxins